2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Animal Model
PAPER

4142 Daptomycin enhances anti-leukemia efficacy of CAR-T cells by inhibiting glycolysis pathway

Qiqi Zhang, Ruirui Jing2, He Huang, MD, PhD3
1 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
2 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
3 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China

Background

Chimeric antigen receptor T (CAR-T) cell therapy achieves durable remission in relapsed/refractory (R/R) CD19+ B-cell malignancies, yet persistent CAR-T exhaustion driven by tonic CAR signaling frequently leads to disease relapse. Prophylactic antibiotics are routinely administered before CAR-T infusion in clinical practice, but their immunomodulatory effects on CAR-T function remain largely undefined. 

Methods

We performed high-throughput in vitro screening of 96 clinical-grade antibiotics using human CD19 CAR-T cells (CD28 or 4-1BB co-stimulatory domains) derived from healthy donors. CAR-T cells were pretreated with candidate antibiotics for 72 h, followed by flow cytometry profiling of central memory T cell (Tcm, CD62L+CD45RO+) frequency, activation markers (CD25, CD69), exhaustion markers (PD-1, TIM-3, LAG-3), apoptosis, and cytotoxicity against Nalm6 B-ALL cells. Cytometric Bead Array (CBA) was used to measure effector cytokine secretion (IL-2, IFN-γ, TNF-α, Granzyme B). In vivo anti-leukemia efficacy was validated in NSG xenograft B-ALL models with DAP-preconditioned CAR-T cells, monitored via bioluminescent imaging and Kaplan-Meier survival analysis. RNA-seq, Gene Set Enrichment Analysis (GSEA), and Seahorse glycolytic stress assays were applied to dissect metabolic mechanisms of daptomycin (DAP).

Results

Daptomycin was identified as the sole antibiotic that simultaneously elevated Tcm proportion, mitigated exhaustion, and enhanced CAR-T cytotoxicity across two healthy donor-derived CAR-T products. In both CD28 and 4-1BB-based CD19 CAR-T constructs, DAP treatment dose-dependently preserved the central memory signiture of CAR-T cells, downregulated CD69 activation signature, reduced PD-1/TIM-3/LAG-3 exhaustion markers, and suppressed CAR-T apoptosis. When co-cultured with Nalm6 leukemia cells, daptomycin-pretreated CAR-T cells retained a higher Tcm frequency and mounted stronger antigen-specific cytotoxic responses. In NSG xenograft mice, adoptive transfer of DAP-pretreated CAR-T cells markedly reduced systemic leukemia burden, prolonged disease remission, and extended overall survival in a concentration-dependent manner. Meanwhile, in-vivo CAR-T persistence was significantly improved after DAP pretreatment. Transcriptomic and Seahorse metabolic assays confirmed DAP globally repressed glycolysis pathway gene expression and diminished basal glycolysis, maximal glycolytic capacity, and glycolytic reserve in CAR-T cells. 

Conclusion

As a clinically approved cyclic lipopeptide antibiotic, daptomycin rewires CAR-T metabolic programs via glycolysis inhibition to expand central memory CAR-T subsets, alleviate tonic signaling-induced exhaustion, and amplify in vivo anti-leukemia efficacy. This work establishes a readily translatable antibiotic-based metabolic conditioning strategy to overcome CAR-T dysfunction for R/R B-cell leukemia, supporting further clinical evaluation of DAP-adjuvanted CAR-T cell manufacturing and infusion protocols.
Qiqi Zhang: No relevant conflicts of interest to declare.